Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities
Key facts
- Where
- Augsburg, NémetországSee the site
Where in Németország
- University Hospital AugsburgAugsburg, NémetországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Christina Berr. MD
- Trial code
- NCT07857044
- Record updated
- 2026. október 5.
- Original description
Pulmonary vein isolation is an established intervention for atrial fibrillation. Patients with a paroxysmal atrial fibrillation have no or only few comorbidities and a good prognosis in respect to their atrial fibrillation. In contrast, patients with persistent atrial fibrillation often suffer from relevant comorbidities and recurrence of atrial fibrillation is common. Left-atrial fibrosis and its electrophysiological consequences are involved in the recurrence rate, but pathophysiological mechanisms are yet to be better characterized. The study investigates relevant comorbidities to elucidated their effect on atrial fibrosis and recurrence rates of atrial fibrillation. Furthermore, the investigators evaluate the prevalence of these comorbidities.Read full original descriptionShow less
Left-atrial Fibrosis in Persistent Atrial Fibrillation, Sleep Apnoe and Primary Aldosteronism
Pulmonary vein isolation is an established intervention for atrial fibrillation. Patients with a paroxysmal atrial fibrillation have no or only few comorbidities and a good prognosis in respect to their atrial fibrillation. In contrast, patients with persistent atrial fibrillation often suffer from relevant comorbidities and recurrence of atrial fibrillation is common. Left-atrial fibrosis and its electrophysiological consequences are involved in the recurrence rate, but pathophysiological mechanisms are yet to be better characterized. The study investigates relevant comorbidities to elucidated their effect on atrial fibrosis and recurrence rates of atrial fibrillation. Furthermore, the investigators evaluate the prevalence of these comorbidities.
Inclusion: persistent atrial fibrillation, eligible for ablation; BMI 19-40.
Exclusion: medication interfereing with measurements of atrial fibrosis; valvular atrial fibrillation; formerly ablation; known or treated comorbidities (OSAS, PA).